Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF13 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF13 receptor and having a sequence identical to the sequence of either one of the human SNORF13a receptor-encoding nucleic acid contained in plasmid pEXJ.T3T7hSNORF13a-f (Patent Deposit Designation No. PTA-______), the human SNORF13b receptor-encoding nucleic acid contained in plasmid pEXJ.T3T7-hSNORF13b-f (Patent Deposit Designation No. PTA-______), the human SNORF13c receptor-encoding nucleic acid contained in plasmid pEXJ.T3T7-hSNORF13c-f (Patent Deposit Designation No. PTA-______), or the human SNORF13d receptor-encoding nucleic acid contained in plasmid pEXJ.T3T7-hSNORF13d-f (Patent Deposit Designation No.

Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides an isolated nucleic acid encoding a human hp15a receptor, a purified human hp15a receptor, vectors comprising isolated nucleic acid encoding a human hp15a receptor, cells comprising such vectors, antibodies directed to a human hp15a receptor, nucleic acid probes useful for detecting nucleic acid encoding a human hp15a receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a human hp15a receptor, transgenic, nonhuman animals which express DNA encoding a normal or mutant human hp15a receptor, methods of isolating a human hp15a receptor, methods of treating an abnormality that is linked to the activity of the human hp15a receptor, as well as methods of determining binding of compounds to human hp15a receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF65 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF65 receptor and having a sequence identical to the sequence of the human SNORF65 receptor-encoding nucleic acid contained in plasmid pEXJ.T3T7-hSNORF65-f (Patent Deposit Designation No. PTA 1226). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF65 receptor, wherein the human SNORF65 receptor comprises an amino acid sequence identical to the sequence of the human SNORF65 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF53 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF53 receptor and having a sequence identical to the sequence of the human SNORF53 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF53-f (Patent Deposit Designation No. PTA ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF53 receptor, wherein the human SNORF53 receptor comprises an amino acid sequence identical to the sequence of the human SNORF53 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1E (SEQ ID NO: 1).

Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's abnormality. This invention further provides a method of treating pain, particularly chronic pain, chronic inflammatory pain and arthritic pain, which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's pain.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF9 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF9 receptor and having a sequence identical to the sequence of the human SNORF9 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF9-f (Patent Deposit Designation No. PTA ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF9 receptor, wherein the human SNORF9 receptor comprises an amino acid sequence identical to the sequence of the human SNORF9 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF12 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF12 receptor and having a sequence identical to the sequence of the human SNORF12 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF12-f (ATCC Accession No. ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF12 receptor, wherein the human SNORF12 receptor comprises an amino acid sequence identical to the sequence of the human SNORF12 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF10 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF10 receptor and having a sequence identical to the sequence of the human SNORF10 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF10-f (ATCC Accession No. ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF10 receptor, wherein the human SNORF10 receptor comprises an amino acid sequence identical to the sequence of the human SNORF10 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1D (Seq. I.D. No. 1).